WO2016108586A1 - 안정성이 증가된 글루카곤 유도체 - Google Patents

안정성이 증가된 글루카곤 유도체 Download PDF

Info

Publication number
WO2016108586A1
WO2016108586A1 PCT/KR2015/014422 KR2015014422W WO2016108586A1 WO 2016108586 A1 WO2016108586 A1 WO 2016108586A1 KR 2015014422 W KR2015014422 W KR 2015014422W WO 2016108586 A1 WO2016108586 A1 WO 2016108586A1
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
glucagon
acid
obesity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/014422
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김정국
이종민
김상윤
배성민
정성엽
권세창
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PH1/2017/501222A priority Critical patent/PH12017501222B1/en
Priority to TN2017000271A priority patent/TN2017000271A1/en
Priority to SG11201705376SA priority patent/SG11201705376SA/en
Priority to MA40709A priority patent/MA40709B1/fr
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority to UAA201707040A priority patent/UA126960C2/uk
Priority to US15/540,729 priority patent/US11135271B2/en
Priority to EP15875680.9A priority patent/EP3241841A4/en
Priority to CN201580077186.3A priority patent/CN107636009B/zh
Priority to HK18104685.2A priority patent/HK1248713A1/en
Priority to JP2017535417A priority patent/JP6797122B2/ja
Priority to CA2972748A priority patent/CA2972748C/en
Priority to NZ733464A priority patent/NZ733464B2/en
Priority to EP19172184.4A priority patent/EP3575314B1/en
Priority to MX2017008569A priority patent/MX2017008569A/es
Priority to PE2022001996A priority patent/PE20230304A1/es
Priority to CR20170293A priority patent/CR20170293A/es
Priority to BR112017014205-8A priority patent/BR112017014205B1/pt
Priority to AU2015372818A priority patent/AU2015372818A1/en
Priority to MYPI2017000967A priority patent/MY185334A/en
Priority to EA201791333A priority patent/EA035527B1/ru
Publication of WO2016108586A1 publication Critical patent/WO2016108586A1/ko
Priority to IL253206A priority patent/IL253206B/en
Priority to CONC2017/0006308A priority patent/CO2017006308A2/es
Anticipated expiration legal-status Critical
Priority to ZA2017/05015A priority patent/ZA201705015B/en
Priority to IL281375A priority patent/IL281375B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Definitions

  • overweight and obese increases blood pressure and cholesterol levels, causing the onset or worsening of various diseases such as heart disease, diabetes, arthritis, and the like.
  • overweight and obesity have become a major factor in increasing the incidence of atherosclerosis, hypertension, hyperlipidemia or heart disease in adults as well as children and adolescents.
  • Exendin-4 made from lizard venom with approximately 50% amino acid homology with GLP-1, is also known to activate the GLP-1 receptor to reduce hyperglycemia in diabetic patients.
  • drugs for treating obesity including GLP-1 or exendin-4, exhibit problems that cause side effects of vomiting and nausea.
  • X7 is threonine or valine
  • X24 is valine, leucine, glutamine or arginine
  • X27 is isoleucine or methionine
  • the glucagon derivative comprising the amino acid sequence of Formula 1 is a substitution, addition deletion or post-translational modification of an amino acid in the sequence of natural glucagon set forth in SEQ ID NO: 1 (eg, methylation, Silicified, ubiquitated, intramolecular covalent bonds), which have an altered pI compared to natural glucagon while maintaining glucagon receptor activity, resulting in increased solubility with pH of the solution, thereby enhancing chemical stability in vivo Encompasses peptides.
  • SEQ ID NO: 1 eg, methylation, Silicified, ubiquitated, intramolecular covalent bonds
  • Such polymers are preferably water-soluble (amphiphilic or hydrophilic), non-toxic and pharmaceutically inert, preferably homo-polymers or co-polymers of PEG, PEG, monomethyl-substituted polymers of PEG (mPEG) Or poly-amino acids such as poly-lysine, poly-aspartic acid and poly-glutamic acid.
  • the pharmaceutical composition of the present invention includes a glucagon derivative having a different pI, which is changed compared to natural glucagon, as an active ingredient, it exhibits improved solubility and high stability according to the pH of the solution, thereby providing stable glucagon for treating hypoglycemia or obesity. It can be usefully used in the preparation of the formulation.
  • the present invention provides a method for preventing or treating hypoglycemia or obesity, comprising administering to a subject the glucagon derivative or a pharmaceutical composition comprising the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/KR2015/014422 2014-12-30 2015-12-30 안정성이 증가된 글루카곤 유도체 Ceased WO2016108586A1 (ko)

Priority Applications (24)

Application Number Priority Date Filing Date Title
NZ733464A NZ733464B2 (en) 2015-12-30 Glucagon derivatives with improved stability
SG11201705376SA SG11201705376SA (en) 2014-12-30 2015-12-30 Glucagon derivative having improved stability
MA40709A MA40709B1 (fr) 2014-12-30 2015-12-30 Dérivé du glucagon à stabilité améliorée
MX2017008569A MX2017008569A (es) 2014-12-30 2015-12-30 Derivados de glucagon con estabilidad mejorada.
UAA201707040A UA126960C2 (uk) 2014-12-30 2015-12-30 Похідна глюкагону
US15/540,729 US11135271B2 (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability
EP15875680.9A EP3241841A4 (en) 2014-12-30 2015-12-30 Glucagon derivative having improved stability
CN201580077186.3A CN107636009B (zh) 2014-12-30 2015-12-30 具有改善的稳定性的胰高血糖素衍生物
HK18104685.2A HK1248713A1 (en) 2014-12-30 2015-12-30 Glucagon derivative having improved stability
JP2017535417A JP6797122B2 (ja) 2014-12-30 2015-12-30 安定性が増加されたグルカゴン誘導体
CA2972748A CA2972748C (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability
MYPI2017000967A MY185334A (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability
EP19172184.4A EP3575314B1 (en) 2014-12-30 2015-12-30 Glucagon derivative
PH1/2017/501222A PH12017501222B1 (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability
PE2022001996A PE20230304A1 (es) 2014-12-30 2015-12-30 Derivados de glucagon como agentes hipoglucemicos y antiobesidad
CR20170293A CR20170293A (es) 2014-12-30 2015-12-30 Derivados de glucagón con estabilidad mejorada
BR112017014205-8A BR112017014205B1 (pt) 2014-12-30 2015-12-30 Derivados de glucagon e seu uso, e uso de uma composição farmacêutica
AU2015372818A AU2015372818A1 (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability
TN2017000271A TN2017000271A1 (en) 2014-12-30 2015-12-30 Glucagon derivative having improved stability
EA201791333A EA035527B1 (ru) 2014-12-30 2015-12-30 Производные глюкагона с улучшенной стабильностью
IL253206A IL253206B (en) 2014-12-30 2017-06-27 Glucagon derivatives with improved stability
CONC2017/0006308A CO2017006308A2 (es) 2014-12-30 2017-06-27 Derivados de glucagón
ZA2017/05015A ZA201705015B (en) 2014-12-30 2017-07-24 Glucagon derivatives with improved stability
IL281375A IL281375B (en) 2014-12-30 2021-03-09 Glucagon derivatives have improved stability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0193800 2014-12-30
KR20140193800 2014-12-30

Publications (1)

Publication Number Publication Date
WO2016108586A1 true WO2016108586A1 (ko) 2016-07-07

Family

ID=56284642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/014422 Ceased WO2016108586A1 (ko) 2014-12-30 2015-12-30 안정성이 증가된 글루카곤 유도체

Country Status (28)

Country Link
US (1) US11135271B2 (OSRAM)
EP (2) EP3241841A4 (OSRAM)
JP (2) JP6797122B2 (OSRAM)
KR (1) KR102291020B1 (OSRAM)
CN (1) CN107636009B (OSRAM)
AR (1) AR103322A1 (OSRAM)
AU (1) AU2015372818A1 (OSRAM)
CL (1) CL2017001718A1 (OSRAM)
CO (1) CO2017006308A2 (OSRAM)
CR (1) CR20170293A (OSRAM)
DO (1) DOP2017000156A (OSRAM)
EA (1) EA035527B1 (OSRAM)
EC (1) ECSP17040923A (OSRAM)
ES (1) ES2976562T3 (OSRAM)
GT (1) GT201700150A (OSRAM)
HK (1) HK1248713A1 (OSRAM)
IL (2) IL253206B (OSRAM)
MA (1) MA40709B1 (OSRAM)
MX (1) MX2017008569A (OSRAM)
MY (1) MY185334A (OSRAM)
PE (2) PE20230304A1 (OSRAM)
PH (1) PH12017501222B1 (OSRAM)
SG (1) SG11201705376SA (OSRAM)
TN (1) TN2017000271A1 (OSRAM)
TW (1) TW201639878A (OSRAM)
UA (1) UA126960C2 (OSRAM)
WO (1) WO2016108586A1 (OSRAM)
ZA (1) ZA201705015B (OSRAM)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9764004B2 (en) 2015-10-26 2017-09-19 Eli Lilly And Company Glucagon receptor agonists
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
JP2018526333A (ja) * 2015-06-30 2018-09-13 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体及びその持続型結合体を含む組成物
KR20190076909A (ko) * 2017-12-22 2019-07-02 한미약품 주식회사 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
US10370426B2 (en) 2015-12-31 2019-08-06 Hanmi Pharm. Co., Ltd Triple glucagon/GLP-1/GIP receptor agonist
AU2017289014B2 (en) * 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
WO2021235907A1 (ko) 2020-05-22 2021-11-25 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
WO2022015082A1 (ko) 2020-07-15 2022-01-20 한미약품 주식회사 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
WO2022216129A1 (ko) 2021-04-09 2022-10-13 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
WO2023121370A1 (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007768A (es) * 2018-01-23 2020-11-12 Xeris Pharmaceuticals Inc Tratamiento contra hipoglucemia posbariátrica usando pequeñas dosis de glucagón estable.
KR20200078414A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8507428B2 (en) * 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
JP5476304B2 (ja) * 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
CA2800389A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
WO2008155900A1 (ja) 2007-06-19 2008-12-24 Otsuka Chemical Co., Ltd. 糖鎖付加glp-1ペプチド
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
NZ601167A (en) * 2010-01-20 2014-12-24 Zealand Pharma As Treatment of cardiac conditions
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
AR086866A1 (es) 2011-06-10 2014-01-29 Hanmi Science Co Ltd Derivados de oxintomodulina y composicion farmaceutica que los comprende para el tratamiento de la obesidad
PT2721062T (pt) * 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
US8859491B2 (en) * 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
PL2864350T3 (pl) 2012-06-21 2019-01-31 Indiana University Research And Technology Corporation Analogi glukagonu wykazujące aktywność wobec receptora GIP
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR102311517B1 (ko) 2012-11-06 2021-10-14 한미약품 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
WO2014081864A1 (en) 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
CN116063453A (zh) 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5476304B2 (ja) * 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8507428B2 (en) * 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHABENNE ET AL.: "A Glucagon Analog Chemically stabilized for Immediate Treatment of Life Threatening Hypoglycemia", MOLECULAR METABOLISM, vol. 3, January 2014 (2014-01-01), pages 293 - 300, XP055173894, DOI: doi:10.1016/j.molmet.2014.01.006 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11667688B2 (en) 2015-06-30 2023-06-06 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
JP2018526333A (ja) * 2015-06-30 2018-09-13 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体及びその持続型結合体を含む組成物
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US9884093B2 (en) 2015-10-26 2018-02-06 Eli Lilly And Company Glucagon receptor agonists
US9764004B2 (en) 2015-10-26 2017-09-19 Eli Lilly And Company Glucagon receptor agonists
US10370426B2 (en) 2015-12-31 2019-08-06 Hanmi Pharm. Co., Ltd Triple glucagon/GLP-1/GIP receptor agonist
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US10400020B2 (en) 2015-12-31 2019-09-03 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist
AU2017289014B2 (en) * 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
KR20190076909A (ko) * 2017-12-22 2019-07-02 한미약품 주식회사 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
KR102588611B1 (ko) 2017-12-22 2023-10-16 한미약품 주식회사 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
WO2021235907A1 (ko) 2020-05-22 2021-11-25 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
WO2022015082A1 (ko) 2020-07-15 2022-01-20 한미약품 주식회사 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
WO2022216129A1 (ko) 2021-04-09 2022-10-13 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
WO2023121370A1 (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Also Published As

Publication number Publication date
EP3575314A2 (en) 2019-12-04
AU2015372818A1 (en) 2017-07-27
CN107636009B (zh) 2021-04-16
US11135271B2 (en) 2021-10-05
HK1248713A1 (en) 2018-10-19
CA2972748A1 (en) 2016-07-07
MX2017008569A (es) 2017-10-20
NZ770767A (en) 2024-04-26
KR102291020B1 (ko) 2021-08-20
EP3575314B1 (en) 2024-02-14
JP7079301B2 (ja) 2022-06-01
TW201639878A (zh) 2016-11-16
MA40709A1 (fr) 2017-12-29
ES2976562T3 (es) 2024-08-05
MY185334A (en) 2021-05-06
US20170360892A1 (en) 2017-12-21
GT201700150A (es) 2018-12-12
CL2017001718A1 (es) 2018-01-12
IL281375A (en) 2021-04-29
IL253206A0 (en) 2017-08-31
EP3241841A4 (en) 2018-10-17
BR112017014205A2 (pt) 2018-03-06
MA40709B1 (fr) 2019-07-31
AR103322A1 (es) 2017-05-03
IL253206B (en) 2021-10-31
PH12017501222B1 (en) 2024-07-03
EA035527B1 (ru) 2020-06-30
JP2020188819A (ja) 2020-11-26
ZA201705015B (en) 2018-04-25
EP3575314A3 (en) 2020-01-22
TN2017000271A1 (en) 2018-10-19
PE20171154A1 (es) 2017-08-16
ECSP17040923A (es) 2017-12-01
EA201791333A1 (ru) 2017-12-29
UA126960C2 (uk) 2023-03-01
IL281375B (en) 2021-10-31
PH12017501222A1 (en) 2018-01-15
KR20160082482A (ko) 2016-07-08
PE20230304A1 (es) 2023-02-13
DOP2017000156A (es) 2017-10-15
JP6797122B2 (ja) 2020-12-09
JP2018504901A (ja) 2018-02-22
EP3241841A1 (en) 2017-11-08
NZ733464A (en) 2024-01-26
CR20170293A (es) 2017-11-03
SG11201705376SA (en) 2017-08-30
CO2017006308A2 (es) 2017-09-29
CN107636009A (zh) 2018-01-26
EP3575314C0 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
WO2016108586A1 (ko) 안정성이 증가된 글루카곤 유도체
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
WO2012169798A2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US12018060B2 (en) Glucagon derivatives
IL263934B2 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
WO2020017916A1 (en) Pharmaceutical composition comprising polypeptide
CA2972748C (en) Glucagon derivatives with improved stability
HK40010066A (en) Glucagon derivative
HK40010066B (en) Glucagon derivative
HK1246323B (en) Glucagon derivatives
HK1255834B (en) Triple activator activating glucagon, glp-1 and gip receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15875680

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: NC2017/0006308

Country of ref document: CO

Ref document number: MX/A/2017/008569

Country of ref document: MX

Ref document number: 253206

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2017293

Country of ref document: CR

Ref document number: 001168-2017

Country of ref document: PE

Ref document number: CR2017-000293

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2972748

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15540729

Country of ref document: US

Ref document number: 12017501222

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2017535417

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11201705376S

Country of ref document: SG

REEP Request for entry into the european phase

Ref document number: 2015875680

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017014205

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 201791333

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: DZP2017000419

Country of ref document: DZ

Ref document number: 40709

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 2015372818

Country of ref document: AU

Date of ref document: 20151230

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201707040

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112017014205

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170629